The potential of amoeba-based processes for natural product syntheses.
Journal
Current opinion in biotechnology
ISSN: 1879-0429
Titre abrégé: Curr Opin Biotechnol
Pays: England
ID NLM: 9100492
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
24
06
2022
revised:
11
07
2022
accepted:
12
07
2022
pubmed:
10
8
2022
medline:
14
9
2022
entrez:
9
8
2022
Statut:
ppublish
Résumé
The identification of novel platform organisms for the production and discovery of small molecules is of high interest for the pharmaceutical industry. In particular, the structural complexity of most natural products with therapeutic potential restricts an industrial production since chemical syntheses often require complex multistep routes. The amoeba Dictyostelium discoideum can be easily cultivated in bioreactors due to its planktonic growth behavior and contains numerous polyketide and terpene synthase genes with only a few compounds being already elucidated. Hence, the amoeba both bears a wealth of hidden natural products and allows for the development of new bioprocesses for existing pharmaceuticals. In this mini review, we present D. discoideum as a novel platform for the production of complex secondary metabolites and discuss its suitability for industrial processes. We also provide initial insights into future bioprocesses, both involving bacterial coculture setups and for the production of plant-based pharmaceuticals.
Identifiants
pubmed: 35944344
pii: S0958-1669(22)00100-8
doi: 10.1016/j.copbio.2022.102766
pii:
doi:
Substances chimiques
Biological Products
0
Pharmaceutical Preparations
0
Types de publication
Journal Article
Review
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
102766Informations de copyright
Copyright © 2022 The Author(s). Published by Elsevier Ltd.. All rights reserved.